New Sjögren's drug shows promise in early safety trial
NCT ID NCT06484855
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This early-stage study tested a new drug called IBI355 in 30 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The main goal was to check the drug's safety and how the body processes it. Researchers gave multiple doses to see if it could help control the condition, but this was not a cure trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230001, China
Conditions
Explore the condition pages connected to this study.